Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04896697 · ClinicalTrials.gov registry record · Phase 1

Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by Xilio Development.

Recruiting
Registry status
Phase 1
Development phase
136
Enrollment target
19
Study locations

NCT04896697 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Xilio Development. The registered enrollment target is 136 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (29% lower). The trial reports 19 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04896697, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Xilio Development.

RECRUITING
Registry status
Phase 1
Development phase
136 participants
Enrollment target
19
Study locations

Study Summary

This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of vilastobart (XTX101) as monotherapy and vilastobart (XTX101) and atezolizumab combination therapy in patients with advanced solid tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Atezolizumab
  • DRUG vilastobart (XTX101)

Study Locations (19)

California

  • City of Hope - Duarte
  • California Cancer Associates for Research and Excellence, cCARE - Encinitas
  • City of Hope-Lennar - Irvine
  • USC/Norris Comprehensive Cancer Center - Los Angeles
  • California Cancer Associates for Research and Excellence, cCARE - San Marcos
  • UCLA Hematology/Oncology- Santa Monica - Santa Monica
  • City of Hope-Upland - Upland

Texas

  • Next Oncology - Austin
  • Mary Crowley Cancer Research - Dallas
  • Tranquil Clinical Research - Webster

Florida

  • Mayo Clinic Hospital - Jacksonville
  • Sarah Cannon Research Institute at Florida Cancer Specialists - Orlando

North Carolina

  • Duke University Medical Center - Durham
  • Carolina BioOncology Institute - Huntersville

Arizona

  • Mayo Clinic Hospital - Phoenix

Massachusetts

  • Massachusetts General Hospital - Boston

Minnesota

  • Mayo Clinic Hospital - Rochester

Pennsylvania

  • University of Pittsburgh Medical Center- Hillman Cancer Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2021-09-13
Est. Completion 2026-03-30
Phase Phase 1

Sponsor

Xilio Development

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04896697

The ClinicalTrials.gov registry entry for NCT04896697 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (29% lower). The listed sponsor is Xilio Development, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.

NCT04896697 reports 19 study locations spanning 9 distinct geographic areas - top geographies include California, Texas, Florida.

Frequently Asked Questions

What is clinical trial NCT04896697 about?

NCT04896697 is a clinical study titled "Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors". This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of vilastobart (XTX101) as monotherapy and vilastobart (XTX101) and atezolizumab combination therapy in patients with advanced solid tumors.

What is the current status of trial NCT04896697?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2021-09-13. Estimated completion is 2026-03-30.

What conditions does trial NCT04896697 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT04896697?

The interventions under investigation include: Atezolizumab (DRUG), vilastobart (XTX101) (DRUG).

Who is sponsoring clinical trial NCT04896697?

This trial is sponsored by Xilio Development, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04896697 being conducted?

This trial has 19 study locations across Arizona, California, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.